Tolebrutinib Phase 3 Trials in MS
A randomized, double-blind Ph3 RMS trial to assess efficacy of once-daily tolebrutinb vs 14mg teriflunomide measured by ARR, as well as disability progression, MRI, cognition, QoL, safety, pharmacodynamics and pharmacokinetics.
This study has been fully enrolled.
Additional Resources
COMPOUND*
CATEGORY*
KEYWORD*
KEYWORD
*indicates a required field
Results ()
All
+
Publication
+
Video
+
Poster
+
Website
+
Can’t find what you’re looking for?
Find an MSL near you.
MAT-US-2308934 v2.0-P
Exp. Date 01/09/2026©2024 Genzyme Corporation. All rights reserved.Sanofi is a registered trademark of Sanofi or an affiliate.
Additional Resources
Resource Library
COMPOUND*
CATEGORY*
KEYWORD*
KEYWORD
*indicates a required field
Results ()
All
Publication
Video
Poster
Website
MAT-US-2308934 v2.0-P
Exp. Date 01/09/2026©2024 Genzyme Corporation. All rights reserved.Sanofi is a registered trademark of Sanofi or an affiliate.